

ACAAI COVID-19 VACCINE COMPARISON CHART – 8/16/21

Vaccine	Pfizer-BioNTech	Moderna	J& J Vaccine
Mechanism of action	Vaccine contains 30 mcg of a nucleoside-modified messenger RNA (mod RNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2	Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.	Replication-incompetent adenovirus type 26 (Ad26)- vector vaccine encoding a stabilized variant of the SARS-CoV-2 S protein
Dose	0.3 ml	0.5 ml	0 .5 ml
Schedule	2 doses, 21 days apart	2 doses, 28 days apart	1 dose
Immunocompromised	3 <sup>rd</sup> dose, at least 28 days after second dose	3 <sup>rd</sup> dose, at least 28 days after second dose	Not approved
Storage	<p>1. Vials must be kept frozen between -80°C to -60°C (-112°F to -76°F) and protected from light.</p> <p>2. If an ultra-low temperature freezer is not available, the thermal container may be used as temporary storage</p> <p>3. Thaw and then store undiluted vials in the refrigerator [2°C to 8°C (35°F to 46°F)] for up to 5 days (120 hours)</p> <p>4 For immediate use, thaw undiluted vials at room temperature [up to 25°C (77°F)] for 30 minutes.</p> <p>5. Undiluted vials may be stored at room temperature for no more than 2 hours.</p>	<p>1. Vaccine multiple-dose vials are stored frozen between -25° to -15°C (-13° to 5°F protected from light.</p> <p>2. Do not store on dry ice or below -40°C (-40°F).</p> <p>3. Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use.</p> <p>4. Unpunctured vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours.</p> <p>5. After the first dose has been withdrawn, the vial should be held between 2° to 25°C (36° to 77°F). Discard vial after 6 hours. Do not refreeze</p>	<p>1. Stored at 2°C to 8°C (36°F to 46°F)] in a multi-dose vial containing 5 doses, protected from light.</p> <p>2. Unpunctured vials may be stored between 9°C to 25°C (47°F to 77°F) for up to 12 hours.</p> <p>2. After withdrawal of first dose, the vial should be held between 2° to 8°C (36° to 46°F) for up to 6 hours or at room temperature for up to 2 hours.</p>
Age approved	12 and up	18 and up	18 and up
Efficacy against Moderate to Severe COVID-19	<p>7 days after second dose.</p> <p>18-64 years - 95.1%</p> <p>65 years and above - 94.7%</p>	<p>14 days after second dose.</p> <p>18 - &lt; 65 years – 95.6 %</p> <p>&gt;65 years – 86.4 %</p>	<p>28 days after dose</p> <p>18- 59 years – 66.1%</p> <p>&gt;60 years - 66.2 %</p> <p>US 72.0%</p> <p>South Africa 64.0%</p> <p>Brazil 68 .1 %</p>

ACAAI COVID-19 VACCINE COMPARISON CHART – 8/16/21

VAERS	Mandatory Reporting of adverse events Including MIS, hospitalization/ fatal COVID	Mandatory Reporting of adverse events including MIS, hospitalization/ fatal COVID	Mandatory Reporting of adverse events including MIS, hospitalization/ fatal COVID																																																																			
Safety Patient self-reporting	Vsafe	Vsafe	Vsafe																																																																			
Adverse events																																																																						
Solicited adverse reactions within 7 days after each dose.	<p>Lasted 2-3 days, more adverse reactions after second dose</p> <table border="1"> <thead> <tr> <th>Dose (%)</th> <th>1</th> <th>2</th> </tr> </thead> <tbody> <tr> <td>Pain at site</td> <td>83.1</td> <td>78.0</td> </tr> <tr> <td>Fatigue</td> <td>47.4</td> <td>59.4</td> </tr> <tr> <td>Headache</td> <td>41.9</td> <td>51.7</td> </tr> <tr> <td>Myalgia</td> <td>21.3</td> <td>37.3</td> </tr> <tr> <td>Chills</td> <td>14.0</td> <td>35.1</td> </tr> <tr> <td>Arthralgia</td> <td>11.0</td> <td>21.9</td> </tr> </tbody> </table>	Dose (%)	1	2	Pain at site	83.1	78.0	Fatigue	47.4	59.4	Headache	41.9	51.7	Myalgia	21.3	37.3	Chills	14.0	35.1	Arthralgia	11.0	21.9	<p>Lasted 2-3 days, more adverse reactions after second dose</p> <table border="1"> <thead> <tr> <th>Dose( %)</th> <th>1</th> <th>2</th> </tr> </thead> <tbody> <tr> <td>Pain at site</td> <td>86.9</td> <td>89.9</td> </tr> <tr> <td>Fatigue.</td> <td>38.</td> <td></td> </tr> <tr> <td>Headache</td> <td>24.5.</td> <td>19.3</td> </tr> <tr> <td>Myalgia.</td> <td>23.7</td> <td></td> </tr> <tr> <td></td> <td>61.6</td> <td></td> </tr> <tr> <td>Chills</td> <td>9.2</td> <td></td> </tr> <tr> <td></td> <td>8.6</td> <td></td> </tr> <tr> <td>Arthralgia</td> <td>16.6</td> <td></td> </tr> <tr> <td></td> <td>45.5</td> <td></td> </tr> </tbody> </table>	Dose( %)	1	2	Pain at site	86.9	89.9	Fatigue.	38.		Headache	24.5.	19.3	Myalgia.	23.7			61.6		Chills	9.2			8.6		Arthralgia	16.6			45.5		<p>(%)</p> <table border="1"> <tbody> <tr> <td>Pain</td> <td>48.6%</td> </tr> <tr> <td>Erythema</td> <td>7.3</td> </tr> <tr> <td>Swelling</td> <td>5.3</td> </tr> <tr> <td>Headache</td> <td>38.9</td> </tr> <tr> <td>Fatigue</td> <td>38.2</td> </tr> <tr> <td>Myalgia</td> <td>33.2</td> </tr> <tr> <td>Nausea</td> <td>14.2</td> </tr> <tr> <td>Fever</td> <td>9.0</td> </tr> </tbody> </table>	Pain	48.6%	Erythema	7.3	Swelling	5.3	Headache	38.9	Fatigue	38.2	Myalgia	33.2	Nausea	14.2	Fever	9.0
Dose (%)	1	2																																																																				
Pain at site	83.1	78.0																																																																				
Fatigue	47.4	59.4																																																																				
Headache	41.9	51.7																																																																				
Myalgia	21.3	37.3																																																																				
Chills	14.0	35.1																																																																				
Arthralgia	11.0	21.9																																																																				
Dose( %)	1	2																																																																				
Pain at site	86.9	89.9																																																																				
Fatigue.	38.																																																																					
Headache	24.5.	19.3																																																																				
Myalgia.	23.7																																																																					
	61.6																																																																					
Chills	9.2																																																																					
	8.6																																																																					
Arthralgia	16.6																																																																					
	45.5																																																																					
Pain	48.6%																																																																					
Erythema	7.3																																																																					
Swelling	5.3																																																																					
Headache	38.9																																																																					
Fatigue	38.2																																																																					
Myalgia	33.2																																																																					
Nausea	14.2																																																																					
Fever	9.0																																																																					
Unsolicited	<p>a) 12 cases of appendicitis reported                      b) Anaphylaxis -reported after EUA with first dose                      c) Myocarditis and pericarditis particularly following second dose                      d) Syncope                      e) Immunocompromised persons may have diminished response</p>	<p>a) 3 cases of Bell’s palsy reported 22,28, 32 days after vaccination –                      b) 2 cases Facial swelling in vaccine recipients with history of dermatological fillers in 1-2 days                      c) 1 case of nausea, vomiting 1 day after vaccination                      d) allergic reaction being investigated after EUA with first dose                      e) large local vaccine site reaction onset after day 7/8                      f) Myocarditis and pericarditis particularly following second dose                      g) Immunocompromised persons may have diminished response</p>	<p>a) embolic and thrombotic events- 0.06% of vaccine recipients                      b) Tinnitus was reported in 6 vaccine recipients                      c) angioedema 0.2% of vaccine recipients                      d) urticaria                      e) arthritis (0.5%)                      f) peripheral neuropathy (0.2%)                      e) Guillain Barre Syndrome</p>																																																																			

ACAAI COVID-19 VACCINE COMPARISON CHART – 8/16/21

<p>Ingredients</p>	<p>1. Lipids - 0.43 mg (4-hydroxybutyl) azanediyl), bis(hexane-6,1-diy)bis(2-hexyldecanoate), 0.05 mg 2[(polyethylene glycol)-2000], N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, 0.2 mg cholesterol)                  2. 0.01 mg potassium chloride                  3. 0.01 mg monobasic potassium phosphate                  4. 0.36 mg sodium chloride                  5. 0.07 mg dibasic sodium phosphate dihydrate,                  6. 6 mg sucrose</p>	<p>1. Lipids- 1.93 mg (SM-102, polyethylene glycol [PEG] 2000,dimyristoyl glycerol [DMG], cholesterol,1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC])                  2. 0.31 mg tromethamine,                  3. 1.18 mg tromethamine hydrochloride,                  4. .043 mg acetic acid, 0.12 mg sodium acetate                  5. 43.5 mg sucrose.</p>	<p>1.Polysorbate 80 2. Citric acid mono hydrate                  3.Trisodium citrate dihydrate                  4.Hydroxypropyl Sodium chloride                  5. Sodium hydroxide                  6. Hydrochloric acid</p>
--------------------	---	---	--